IOVANCE Aktie

>IOVANCE Aktienkurs

1.9612 EUR -4.7% (Tradegate)

Ask: 1.9524 EUR / 15400 Stück

Bid: 1.9246 EUR / 15600 Stück

Tagesumsatz: 35336 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

IOVANCE Aktie über LYNX handeln

Intraday

1 Jahr

>IOVANCE Performance

1 Woche: -7,0%

1 Monat: +3,2%

3 Monate: +1,0%

6 Monate: -43,3%

1 Jahr: -77,2%

laufendes Jahr: -71,6%

>IOVANCE Aktie

Name:

IOVANCE BIOTHERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US4622601007 / A2DT49

Symbol/ Ticker:

2LB (Frankfurt) / IOVA (NASDAQ)

Kürzel:

FRA:2LB, ETR:2LB, 2LB:GR, NASDAQ:IOVA

Index:

Webseite:

https://www.iovance.com/

Profil:

Iovance Biotherapeutics, Inc. is a commercial-stag..
>Volltext..

Marktkapitalisierung:

700.04 Mio. EUR

Unternehmenswert:

489.49 Mio. EUR

Umsatz:

205.84 Mio. EUR

EBITDA:

-310.9 Mio. EUR

Nettogewinn:

-332.31 Mio. EUR

Gewinn je Aktie:

-1.05 EUR

Schulden:

45.31 Mio. EUR

Liquide Mittel:

112.9 Mio. EUR

Operativer Cashflow:

-258.58 Mio. EUR

Bargeldquote:

2.33

Umsatzwachstum:

570.12%

Gewinnwachstum:

19.46%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

IOVANCE

Letzte Datenerhebung:

14.09.25

>IOVANCE Kennzahlen

Aktien/ Unternehmen:

Aktien: 361.85 Mio. St.

Frei handelbar: 80.88%

Leerverk. Aktien: 23.4%

Rückkaufquote: -26.07%

Mitarbeiter: 838

Umsatz/Mitarb.: 0.17 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 289.19%

Bewertung:

KGV: -

KGV lG: -

KUV: 3.29

KBV: 1.16

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 10.81%

Gewinnmarge: -161.44%

Operative Marge: -170.02%

Managementeffizenz:

Gesamtkaprendite: -41.66%

Eigenkaprendite: -53.16%

>IOVANCE Peer Group

Es sind 601 Aktien bekannt.

>IOVANCE Chart & Kurs - NASDAQ

>IOVANCE News

29.08.25 - 14:33	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire EN)
	SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:...

26.08.25 - 16:30	IOVA Stock Drops 6% on $350M Common Stock Offering (Zacks)
	Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline....

25.08.25 - 23:48	Why Iovance Biotherapeutics Stock Got Mashed on Monday (Fool)
	The company announced a flotation of its common shares that is potentially quite dilutive....

22.08.25 - 23:18

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)

SAN CARLOS, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 21, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 182,370 shares of Iovance's common stock to 20 new, non-executive employees....

19.08.25 - 21:48	Why Iovance Biotherapeutics Stock Was Climbing Today (Fool)
	One and a half years after getting the nod from the U.S. Food and Drug Administration, its Amtagvi moves forward in a neighboring country....

18.08.25 - 23:06	Iovance gets conditional Health Canada approval for Amtagvi (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

18.08.25 - 22:18	Iovance′s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma (GlobeNewswire EN)
	First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy...

12.08.25 - 23:33	Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications \| DelveInsight (PR Newswire)
	Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics, Biosyngen, KSQ Therapeutics, and others, are currently engaged in the development and production of......

09.08.25 - 02:24	Why Iovance Biotherapeutics Stock Plummeted Today (Fool)
	The company's top line nearly doubled....

08.08.25 - 21:54	Iovance falls after missing Q2 expectation (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.08.25 - 20:30	IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi (Zacks)
	Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy....

08.08.25 - 09:21	Iovance outlines $250M–$300M 2025 revenue target as restructuring aims to boost margins and expand Amtagvi adoption (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.08.25 - 23:24	Iovance (IOVA) Q2 Revenue Jumps 93% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

07.08.25 - 22:06	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 (GlobeNewswire EN)
	$60.0M in 2Q25 Total Product Revenue...

30.07.25 - 11:24	Is Iovance Biotherapeutics Stock Due for a Big Rally? (Fool)
	The biotech stock has been picking up steam of late -- but will it last?...

23.07.25 - 14:36	Analyst Expectations For Iovance Biotherapeuticss Future (Benzinga)
	Latest Ratings for IOVA DateFirmActionFromTo Feb 2022BairdMaintainsOutperform Feb 2022Chardan CapitalMaintainsBuy Jan 2022StifelUpgradesHoldBuy View More Analyst Ratings for IOVA View the Latest Analyst Ratings read more...

22.07.25 - 17:00	Iovance climbs after FDA rejection for Replimune’s skin cancer drug (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

18.07.25 - 23:18

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)

SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 138,190 shares of Iovance's common stock to 20 new, non-executive employees....

15.07.25 - 13:51	Iovance Biotherapeutics appoints Corleen Roche as chief financial officer (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.07.25 - 15:06	Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm (PR Newswire)
	NEW YORK, July 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wenn eine Frau einen Fehltritt begeht, schiebt sie die Schuld auf die Schuhe, die der Mann ihr gekauft hat. - Louis Bultel

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram